Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Articles|April 1, 2006
- Applied Clinical Trials-04-01-2006
- Volume 0
- Issue 0
18th Annual DIA EuroMeeting
Images from the exhibition and seminar floors at the 18th annual event in Paris, the most well-attended meeting to date.
Advertisement
DIA EuroMeeting
March 6–8, 2006 Paris, France
The DIA reported record-breaking attendance at its 18th Annual EuroMeeting held in Paris, France. The conference proved to be an international success and a neutral forum for the latest information and developments on EU Directive initiatives, pediatric regulations, the Pediatric Committee, technology research and platforms, pharmacogenomics, pharmacovigilance, and risk management.
The 14 tracks gave conference goers more than enough workshops to choose from. The Exhibitors floor was busy with information seekers, networkers, great giveaways, and delightful Parisian pastries.
Articles in this issue
over 20 years ago
Precedents for Good Storage Practiceover 20 years ago
Finding the Right Core ECG Laboratoryover 20 years ago
Forgotten Voices in the Transparency Debateover 20 years ago
Is ERP the Key to Supply Chain Success?over 20 years ago
Clinical Trials in Serbia: From Strong to Strongerover 20 years ago
Brussels Broods over Biomarkersover 20 years ago
Managing the Myriad of FDA MeetingsAdvertisement
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
What Needs to Happen Beyond the Clinical Trial Modernization Act
2
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
3
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
4
ACT Brief: Community Research Access, Trustworthy AI Assistants, and Individualized Gene Editing Guidance
5